{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Molecular Partners AG"},"Symbol":{"label":"Symbol","value":"MOLN"},"Address":{"label":"Address","value":"WAGISTRASSE 14,SCHLIEREN, ZURICH, 8952, Switzerland"},"Phone":{"label":"Phone","value":"+41 447557700"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment."},"CompanyUrl":{"label":"Company Url","value":"https://www.molecularpartners.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Alexander ZÃ¼rcher","title":"Chief Operating Officer"},{"name":"Anne Goubier","title":"Senior VP-Research & Early Development"},{"name":"Baris Arican","title":"Vice President-Information Technology"},{"name":"Daniel Steiner","title":"Senior Vice President-Research & Technology"},{"name":"Patrick Amstutz","title":"Chief Executive Officer & Director"},{"name":"Philippe Legenne","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}